Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) and Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.
Profitability
This table compares Syndax Pharmaceuticals and Regeneron Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Syndax Pharmaceuticals | -72.32% | -517.88% | -36.84% |
| Regeneron Pharmaceuticals | 28.51% | 16.01% | 12.22% |
Insider and Institutional Ownership
83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 4.8% of Syndax Pharmaceuticals shares are held by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Syndax Pharmaceuticals and Regeneron Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Syndax Pharmaceuticals | $172.35 million | 7.35 | -$285.42 million | ($2.51) | -5.69 |
| Regeneron Pharmaceuticals | $14.34 billion | 6.99 | $4.50 billion | $45.29 | 21.49 |
Regeneron Pharmaceuticals has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Syndax Pharmaceuticals has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.1, indicating that its share price is 90% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations for Syndax Pharmaceuticals and Regeneron Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Syndax Pharmaceuticals | 1 | 0 | 10 | 0 | 2.82 |
| Regeneron Pharmaceuticals | 0 | 9 | 21 | 1 | 2.74 |
Syndax Pharmaceuticals currently has a consensus price target of $41.60, suggesting a potential upside of 191.11%. Regeneron Pharmaceuticals has a consensus price target of $898.97, suggesting a potential downside of 7.64%. Given Syndax Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts clearly believe Syndax Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.
Summary
Regeneron Pharmaceuticals beats Syndax Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
